<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: The Fraxiparin in <z:hpo ids='HP_0001297'>Stroke</z:hpo> Study for the treatment of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> (FISS-<z:chebi fb="3" ids="9754">tris</z:chebi>) study showed no superiority of low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (LMWH) over aspirin for the primary end point (Barthel Index) in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> due to large artery occlusive disease </plain></SENT>
<SENT sid="1" pm="."><plain>This study aims to evaluate the efficacy of LMWH and aspirin in selected subgroups so as to generate hypotheses for further studies </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The FISS-<z:chebi fb="3" ids="9754">tris</z:chebi> study was a multicenter, randomized trial to investigate the efficacy and safety of LMWH (nadroparin calcium 3800 antifactor Xa IU/0.4 mL subcutaneously twice daily) or aspirin (160 mg once daily) for the treatment of patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and large artery occlusive disease </plain></SENT>
<SENT sid="3" pm="."><plain>The primary outcome was the Barthel Index score dichotomized at 85 6 months poststroke </plain></SENT>
<SENT sid="4" pm="."><plain>Exploratory subgroup analysis was performed using different levels of baseline characteristics and the distribution of symptomatic arteries </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Compared with aspirin, LMWH improved outcome among older patients &gt;68 years (P=0.043; OR, 1.86; 95% CI, 1.02-3.41) without ongoing antiplatelet treatment on admission (P=0.029; OR, 1.85; 95% CI, 1.06-3.21) and with symptomatic posterior circulation <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arterial disease</z:e> (P=0.001; OR, 5.76; 95% CI, 2.00-16.56) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Our findings suggest that LMWH may be of benefit in certain subgroups of patients with <z:hpo ids='HP_0011009'>acute</z:hpo> cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> and large artery occlusive disease </plain></SENT>
<SENT sid="7" pm="."><plain>Hence, further investigation of LMWH may be justified in subgroups such as the elderly, nonusers of antiplatelet agents, and patients with posterior circulation stenosis </plain></SENT>
<SENT sid="8" pm="."><plain>CLINICAL TRIAL REGISTRATION: URL: www.strokecenter.org/trials </plain></SENT>
<SENT sid="9" pm="."><plain>Unique identifier: registration no. 493 </plain></SENT>
</text></document>